

## References for CEQUA® (cyclosporine ophthalmic solution) 0.09% *ASCRS Side Door (Marriott)*

### References:

1. Schechter BA, Urbieta M, Bacharach J, et al. Effect of OTX-101 in patients with dry eye disease at day 14 of treatment: ocular surface endpoint results from the phase 2b/3 clinical trial. *Clin Ophthalmol.* 2022;16:4145-4151.
2. Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD. A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease. *Ophthalmology.* 2019;126(9):1230-1237.
3. Data on file. Cranbury, NJ; Sun Pharmaceutical Industries, Inc.
4. Tauber J, Schechter BA, Bacharach J, et al. A phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease. *Clin Ophthalmol.* 2018;12:1921-1929.
5. Karpecki P, Barghout V, Schenkel B, et al. A retrospective analysis of real-world treatment patterns in patients with dry eye disease receiving CEQUA, Restasis®, or Xiidra®. Poster presented at AMCP Nexus; October 11-14, 2022; National Harbor, MD.
6. Malhotra R, Devries DK, Luchs J, et al. Effect of OTX-101, a novel nanomicellar formulation of cyclosporine A, on corneal staining in patients with keratoconjunctivitis sicca: a pooled analysis of phase 2b/3 and phase 3 studies. *Cornea.* 2019;38:1259-1265.

© 2023 Sun Ophthalmics, a division of Sun Pharmaceutical Industries, Inc.  
All rights reserved. CEQUA is a registered trademark of Sun Pharmaceutical Industries Limited.  
All other trademarks are the property of their respective owners.  
PM-US-CQA-1230 04/2023

